February 27, 2019 / 5:13 AM / 7 months ago

BRIEF-Blackstone Life Sciences And Novartis Launch Anthos Therapeutics

Feb 27 (Reuters) - Blackstone Life Sciences:

* BLACKSTONE LIFE SCIENCES AND NOVARTIS LAUNCH ANTHOS THERAPEUTICS TO DEVELOP INNOVATIVE MEDICINES FOR CARDIOVASCULAR DISEASE

* BLACKSTONE GROUP LP - BLACKSTONE LIFE SCIENCES PROVIDES $250M FINANCING

* BLACKSTONE GROUP - NOVARTIS HAS LICENSED TO ANTHOS MAA868, AN ANTIBODY DIRECTED AT FACTOR XI AND XIA, KEY COMPONENTS OF INTRINSIC COAGULATION PATHWAY

* BLACKSTONE GROUP LP - NOVARTIS WILL RETAIN A MINORITY EQUITY INTEREST IN ANTHOS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below